Latest News about BMRN
Recent news which mentions BMRN
From Benzinga
Earnings Scheduled For May 1, 2025
May 01, 2025
From Benzinga
From Benzinga
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
April 11, 2025
From Motley Fool
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
April 02, 2025
From Benzinga
5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction
March 27, 2025
From Motley Fool
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
February 20, 2025
Tickers
BMRN
From Motley Fool
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
February 20, 2025
Tickers
BMRN
From Benzinga
Why Is BioMarin Stock Trading Higher On Thursday?
February 20, 2025
From Benzinga
Earnings Scheduled For February 19, 2025
February 19, 2025
From Benzinga
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
From Benzinga
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
January 19, 2025
From Benzinga
From Benzinga
10 Magnificent Stocks That Can Make You Richer in 2025
January 03, 2025
From Motley Fool
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
November 15, 2024
Tickers
BMRN
From Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
November 06, 2024
Tickers
BMRN
From Benzinga
CAMP4 Analyst Highlights Rare Disease Platform Potential
November 05, 2024
From Benzinga
From Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
October 28, 2024
Tickers
BMRN
From Benzinga
How Is The Market Feeling About Biomarin Pharmaceutical?
October 15, 2024
Tickers
BMRN
From Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
October 04, 2024
Tickers
BMRN
From Benzinga
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
September 25, 2024
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.